Clinical & Medical Microbiology

Research Article

Advances in mRNA Vaccine Technology Beyond COVID-19

Neha Singh* and Nikita Sherwani

Virus Research and Diagnostic Laboratory, Department of Microbiology, Pt. JNM Medical College, Raipur, Chhattisgarh, 492001, India.

Corresponding Author Information

Neha Singh

Virus Research and Diagnostic Laboratory, Department of Microbiology, Pt. JNM Medical College, Raipur, Chhattisgarh, 492001, India.

Received: August 20, 2025; **Accepted:** October 01, 2025; **Published:** October 13, 2025

Citation: Neha Singh, Nikita Sherwani. Advances in mRNA Vaccine Technology Beyond COVID-19. Clin Med Microbiol. 2025; 1(1):1-6.

ABSTRACT

The rapid and unprecedented success of mRNA vaccines against the SARS-CoV-2 virus has revolutionized the field of vaccinology, demonstrating the immense potential of this platform. Beyond its pivotal role in combating the COVID-19 pandemic, mRNA vaccine technology is now at the forefront of a new era in medicine, with research and development expanding into a vast array of other infectious diseases, cancer, and even autoimmune and genetic disorders. This review provides a comprehensive overview of the post-COVID-19 landscape of mRNA vaccines. It delves into the fundamental technological advancements that have enhanced their stability, efficacy, and delivery. We explore the promising applications in fighting other infectious pathogens like influenza, HIV, and RSV, and their burgeoning role in personalized cancer immunotherapy. The paper also addresses the current challenges, including manufacturing scalability, cost, and the need for improved thermostability, while outlining the future prospects of this transformative technology. The journey of mRNA vaccines, from a decades-old concept to a cornerstone of modern medicine, highlights their flexibility, speed, and potential to redefine global health.

KEYWORDS

mRNA vaccines, Cancer immunotherapy, Infectious diseases, Lipid nanoparticles, Self-amplifying RNA, Vaccine technology.

Introduction

The global health crisis instigated by the COVID-19 pandemic served as a crucible for the accelerated development and deployment of mRNA vaccines. Before 2020, mRNA technology was a promising but largely unproven concept in clinical medicine [1]. The swift and successful authorization of the Pfizer-BioNTech and Moderna mRNA vaccines, which demonstrated unprecedented efficacy and safety profiles, not only provided a critical tool for pandemic control but also validated the entire mRNA platform [2]. The foundational research, which had been ongoing for decades, was finally realized on a global scale. This success has since catalyzed an explosion of research and investment, shifting the focus from a single pathogen to a diverse portfolio of diseases that were previously difficult to target with conventional vaccines [3]. The advantages of mRNA vaccines are manifold. Them *in-vitro* synthesis allows for a rapid, cell-free production process, which is highly scalable and not dependent on culturing live viruses. The modular nature of the mRNA molecule means that a new vaccine can be designed and manufactured by simply changing the genetic sequence encoding the target antigen [4,5]. Furthermore, mRNA vaccines, when delivered via lipid nanoparticles (LNPs), can elicit robust humoral (antibody) and cellular (T-cell) immune responses without the risk of integration into the host genome [6,7]. This review aims to survey the landscape of mRNA vaccine development in the wake

of the COVID-19 pandemic, focusing on its applications beyond infectious diseases, the key technological innovations driving this expansion, and the challenges that must be overcome to fully harness its potential.

Applications in Infectious Diseases Beyond SARS-CoV-2

The triumphs of mRNA vaccines against COVID-19 have paved the way for their application against a broad spectrum of infectious pathogens. Researchers are now tackling viruses and bacteria that have long evaded traditional vaccine approaches [8]. Figure 1. The Expanding applications of mRNA Vaccines. Illustrated the diverse range of pathogens being targeted by mRNA vaccine technology. including viruses (e.g., Influenza, HIV, RSV, Zika, CMV) and parasites (*Plasmodium falciparum* for malaria). Each pathogen, indicating the current development stage (e.g., "Phase 3 clinical trials," "Early-stage research," "Commercially available").



Figure 1: The Expanding Applications of mRNA Vaccines.

Influenza

Seasonal influenza is a major public health concern, requiring annual vaccine reformulation due to the virus's high mutation rate [9]. Current egg-based or cell-based influenza vaccines often suffer from a long production timeline and moderate efficacy. mRNA vaccines offer a paradigm shift [10]. Companies are developing multivalent mRNA vaccines that can encode antigens from multiple influenza strains (A and B types) in a single shot, providing broader and more durable protection [11]. For example, clinical trials for multivalent seasonal influenza vaccines are in Phase 3, with companies aiming to provide a more convenient and effective annual flu shot. Furthermore, the goal of a "universal influenza vaccine" that protects against all major strains and sub-types is now a tangible possibility, with research underway on mRNA vaccines that encode conserved antigens common to all influenza viruses [9-12].

Human Immunodeficiency Virus (HIV)

Developing an effective HIV vaccine has been a monumental challenge due to the virus's ability to rapidly mutate and evade the immune system [13]. The mRNA platform, with its flexibility, is being leveraged to design vaccines that can induce a specific type of immune response known as broadly neutralizing antibodies (bnAbs) [14]. Researchers are using mRNA to encode complex, multi-component nanoparticle immunogens that can prime the immune system to produce these rare and potent antibodies [12,15]. Phase 1 clinical trials are underway for several mRNA-based HIV vaccine candidates, representing a significant step forward in a field that has seen limited success for decades.

Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus (RSV) is a ubiquitous, enveloped, negative-sense RNA virus from the *Pneumoviridae* family that is a leading cause of severe lower respiratory tract disease in infants and older adults [16]. The development of an effective vaccine for RSV was historically hampered by the risk of vaccine-enhanced respiratory disease (VERD), a severe immunopathology observed in clinical trials of early formalin-inactivated vaccine candidates. A major breakthrough came from structural biology, which identified that the virus's fusion (F) glycoprotein exists in a metastable prefusion (preF) conformation that is the primary target for a robust neutralizing antibody response [17]. The mRNA platform was instrumental in overcoming this challenge by precisely encoding the genetic sequence for a stabilized version of the preF protein [18]. This approach avoids the risks of VERD associated with older vaccine technologies and has led to the successful development and commercial availability of mRNA- based RSV vaccines for older adults [19].

Other Infectious Agents

The versatility of mRNA technology is evident in its application to a wide range of other pathogens [20]. Clinical trials are in progress for mRNA vaccines against a host of diseases, including:

- Zika Virus: A single-dose mRNA vaccine for Zika is in Phase 2 clinical trials.
- Cytomegalovirus (CMV): An mRNA vaccine for CMV, a major cause of birth defects, is in Phase 3 trials.
- Norovirus: Vaccine candidates are being developed to combat this highly contagious cause of gastroenteritis.
- Malaria: Researchers are exploring mRNA vaccines to target the *Plasmodium falciparum* parasite, a significant health challenge in tropical regions.
- Lyme Disease: Vaccines are in development for this tick-borne bacterial infection.

The New Frontier: Cancer Immunotherapy

One of the most exciting and transformative applications of mRNA technology lies in the field of oncology [21]. Here, mRNA vaccines are not used for prevention but as a therapeutic tool to reprogram the body's immune system to recognize and attack cancer cells. Personalized cancer immunotherapy tailors mRNA vaccines to an individual's tumor by identifying specific neoantigens, resulting in a highly targeted immune response. In contrast, universal cancer vaccines use mRNA encoding common tumor-associated antigens or immune enhancers to trigger broader anti-tumor immunity across multiple patients [22]. Personalized vaccines offer precision,

while universal approaches emphasize scalability and accessibility. Figure 2. Showing the comparison of personalized vs. universal cancer immunotherapy.



Figure 2: Comparison of Personalized vs. Universal Cancer Immunotherapy.

This figure present a side-by-side comparison of the two main cancer vaccine approaches. On one side, "Personalized Vaccines" show a diagram of a patient's tumor being biopsied, sequenced, and then used to create a custom mRNA vaccine encoding specific neoantigens. The output would be a targeted immune response against the patient's unique cancer cells. On the other side, "Universal Vaccines" show an mRNA vaccine encoding common cancer-related proteins or an immune-boosting agent, leading to a broader anti-tumor response that could be applied to many patients.

Personalized Cancer Vaccines

Cancer cells often harbor unique mutations that are not present in healthy cells. These mutations give rise to new proteins, called neoantigens, which can serve as ideal targets for the immune system [22,23]. The modularity of mRNA technology allows for the rapid creation of personalized cancer vaccines. In this approach, a patient's tumor is sequenced to identify these specific neoantigens. An mRNA vaccine is then custom-designed to encode the most promising neoantigens, instructing the patient's own cells to produce these proteins and activate a powerful, tumor-specific T-cell response [24]. A Phase 3 trial for a personalized mRNA cancer vaccine for adjuvant melanoma, in combination with an immune checkpoint inhibitor, is currently ongoing. Early-stage trials are also showing promising results in pancreatic cancer and other solid tumors, demonstrating the potential for this approach to become a cornerstone of precision oncology [25].

Universal Cancer Vaccines

Beyond personalized approaches, researchers are also exploring the concept of a "generalized" or universal mRNA cancer vaccine. This type of vaccine would not be targeted at a specific tumor but would be designed to broadly activate the immune system against common cancer- related proteins or to stimulate a generalized anti-tumor response. Recent research has shown that an mRNA vaccine, not specific to any particular tumor, could still boost the tumor-fighting effects of immunotherapy in animal models [2-5,15]. The underlying mechanism seems to be a general revving-up of the immune system to respond as if fighting a virus, which in turn makes tumors more receptive to treatment. This approach could be more scalable and less expensive than personalized vaccines, with the potential to be used in a wider range of patients [9].

Advancements in mRNA Vaccine Technology

The clinical success of mRNA vaccines is the result of decades of foundational research and recent, rapid technological innovations [26]. Key areas of advancement include improvements in mRNA structure, delivery systems, and formulation.



Figure 3: Technological Evolution of mRNA Vaccines.

A comparative diagram showing the progression of mRNA technology. (a) **Conventional mRNA:** A simplified diagram of a linear mRNA strand with a label indicating it only encodes the antigen. (b) **Self-Amplifying mRNA (saRNA):** A diagram of a longer linear mRNA strand that, in addition to the antigen, also encodes a viral replicase enzyme. The replicase making multiple copies of the antigen- encoding mRNA, leading to higher protein production. (c) **Circular mRNA (circRNA):** An mRNA strand in a closed loop, emphasizing its resistance to degradation and its potential for long-lasting protein production.

mRNA Modifications

Early in the development of mRNA vaccines, a major challenge was their inherent instability and high immunogenicity, which could lead to unwanted inflammatory responses. This was largely solved by incorporating modified nucleosides, such as pseudouridine, during the *in vitro* transcription process [26]. This modification prevents the host cell's innate immune sensors from recognizing the exogenous mRNA as foreign, thereby increasing the stability of the molecule and enhancing its translation into the desired antigen protein. This subtle but critical change allowed for a much stronger and more durable immune response [27].

Delivery Systems

The naked mRNA molecule is fragile and susceptible to degradation by enzymes in the body. To overcome this, delivery systems are essential. Lipid Nanoparticles (LNPs) have emerged as the gold standard [28]. These tiny, synthetic fatty particles encapsulate the mRNA, protecting it from degradation and facilitating its entry into cells. Recent research is focused on developing next-generation LNPs with improved targeting capabilities, allowing for more precise delivery to specific cell types (e.g., antigen-presenting cells) and a more potent immune response [29]. New delivery routes, such as intradermal injection, are also being explored to potentially enhance the immune response with a smaller vaccine dose.

Self-Amplifying mRNA (saRNA): A Molecular Replicator

A major innovation is the development of self-amplifying mRNA (saRNA) vaccines. Unlike conventional mRNA, which functions as a transient blueprint for protein production and is quickly degraded, saRNA acts as a molecular "photocopy machine" inside the host cell [21,22]. The fundamental scientific principle behind saRNA is its derivation from the genome of positive-sense single-stranded RNA viruses, most commonly alphaviruses such as the Venezuelan equine encephalitis virus (VEEV) [30]. A conventional mRNA vaccine molecule is relatively short, encoding only the gene for the target antigen (e.g., the SARS-CoV-2 spike protein). In contrast, an saRNA molecule is significantly longer, typically ranging from 9–12 kb. It is engineered to contain two distinct open reading frames (ORFs) within a single RNA strand [27]. The first, and most crucial, ORF encodes the viral non-structural proteins (nsP1- 4), which collectively form the RNA-dependent RNA polymerase (RdRp) complex. The second ORF, which replaces the viral structural proteins, encodes the gene for the desired vaccine antigen [31]. Once the saRNA, encapsulated in a lipid nanoparticle, enters the cytoplasm of a host cell, the host's ribosomes immediately translate the first ORF. This process produces the viral RdRp complex. This newly synthesized RdRp then takes over the cell's machinery, using the original saRNA molecule as a template to create a complementary negative-strand RNA. This negative-strand template is then used to synthesize two new types of RNA:

- More copies of the full-length positive-strand saRNA.
- A large number of smaller subgenomic mRNAs that specifically encode only the target antigen.

This self-amplification process results in a massive, exponential increase in both the number of saRNA molecules and the subgenomic mRNAs. Consequently, a single saRNA vaccine molecule can lead to the production of thousands of antigen protein molecules, whereas a conventional mRNA molecule produces only one or a few [30]. The advantages of this self- amplifying mechanism are profound. By requiring a significantly lower initial dose of RNA to achieve a robust immune response, saRNA vaccines have the potential to reduce manufacturing costs, increase vaccine supply, and potentially lessen the localized inflammatory side effects associated with a high concentration of the first-generation mRNA vaccines [32]. Furthermore, the prolonged and sustained expression of the antigen protein can lead to a more durable and potent immune response, potentially offering longer-lasting protection and requiring fewer booster doses [8,23].

Circular mRNA

Circular mRNA (circRNA) is an emerging technology that represents an even more stable and long-lasting form of mRNA. Unlike linear mRNA, which is susceptible to degradation by enzymes that cleave its ends, circRNA forms a closed loop, making it much more resistant to enzymatic breakdown [33-35]. This feature allows circRNA vaccines to have a longer half-life in the cell, leading to sustained antigen production and potentially more durable immune protection. Although still in the early stages of research, circRNA holds great promise for vaccines that require a long-lasting immune response [36].

Challenges and Future Outlook

Despite the remarkable progress, several significant challenges must be addressed to fully realize the potential of mRNA vaccine technology.

Stability and Cold Chain Requirements

The first-generation mRNA vaccines require ultra-cold storage temperatures (typically −70°C to −80°C), which presents a major logistical challenge, particularly in low- and middle-income countries [30]. This "cold chain" requirement complicates transportation, storage, and distribution. Ongoing research is focused on developing more thermostable formulations and lyophilized (freeze-dried) versions of mRNA vaccines that can be stored at standard refrigeration temperatures, making them more accessible globally [6,31].

Manufacturing and Cost

While mRNA vaccine production is faster and more scalable than traditional methods, the manufacturing process is complex and requires specialized infrastructure and high-purity raw materials [34]. This can result in high production costs, which may limit their affordability and equitable distribution [35]. Efforts are underway to streamline manufacturing processes, improve yields, and develop more cost-effective raw materials.

Immune Response and Adverse Effects

While the safety profile of COVID-19 mRNA vaccines has been excellent, some individuals experience transient side effects like fever and injection site pain [36]. A small subset of individuals may experience more serious, albeit rare, adverse events. Future research will focus on fine-tuning the mRNA and LNP formulations to reduce these reactogenicity signals while maintaining a potent immune response [5,37].

Public Trust and Misinformation

The rapid rollout of the COVID-19 mRNA vaccines, coupled with the newness of the technology, led to widespread misinformation and vaccine hesitancy [19,26]. Building public trust and ensuring clear, accurate communication about the technology, its safety, and its long- term benefits will be critical for the success of future

mRNA vaccines.

Conclusion

The journey of mRNA vaccine technology, accelerated by the exigencies of the COVID-19 pandemic, has been nothing short of a scientific revolution [5,31]. What began as a tool for a single public health crisis has now become a versatile and powerful platform poised to transform medicine. Beyond infectious diseases like influenza, HIV, and RSV, mRNA technology is opening up unprecedented avenues for treating cancer through personalized immunotherapy [34]. Advances in mRNA modifications, delivery systems, and the development of self-amplifying and circular mRNA are continually pushing the boundaries of what is possible. While challenges related to stability, cost, and manufacturing remain, the scientific community is actively working to overcome them. The future of medicine is increasingly an mRNA future, with a promise to deliver rapid, safe, and highly effective therapeutic and preventative solutions for a vast number of diseases.

References

1. Adis H, Kremsner PG. Clinical evaluation of a novel mRNA influenza vaccine. Human Vaccines & Immunotherapeutics. 2019; 15: 2459-2467.
2. Bahl K, Fofana I, Li F. CircRNA vaccines: a new perspective for cancer immunotherapy. Molecular Therapy. 2022; 30: 1802-1811.
3. Cas Insights. The future of mRNA vaccines beyond COVID-19. CAS Insights. 2025.
4. Singh N, Jaiswal J, Sherwani N, Nagaria T, Khandwal O, et al. Maternal and neonatal outcomes associated with COVID-19 infection in pregnant mothers admitted in tertiary care hospital in central state of India. Cureus. 2023; 15.
5. Cui Y, Guo Y, Lu R, Wu C. Challenges in the large-scale manufacturing of mRNA vaccines. Vaccines. 2020; 8: 405.
6. Dolgin E. The mRNA revolution. Nature. 2021; 597: 453-455.
7. Fan Y, Liu X, Wang Q, Zhang J. Progress and challenges in lipid nanoparticle-mediated mRNA delivery for cancer immunotherapy. Journal of Controlled Release. 2023; 356: 442-455.
8. Singh N, Sherwani N, Neral A. Public mental health during COVID-19 pandemic and preventive approaches. PARIPEX - INDIAN JOURNAL OF RESEARCH. 2020; 9: 18-21.
9. Gou M, Yang Z, Chen M, Wang Y. A comprehensive review of mRNA vaccines beyond COVID-19: opportunities and challenges. Drug Discovery Today. 2023; 28: 103445.
10. Singh N, Jain K, Jain S. Wearing face masks for COVID-19 pandemic: From medical tradition to community practice. PARIPEX - INDIAN JOURNAL OF RESEARCH. 2020; 9: 11-13.
11. Singh N, Sherwani N, Jaiswal J, Nagaria T, Neral A, et al. Vertical transmission of SARS-CoV-2 from infected mother to neonates—An experience at tertiary care hospital, Raipur, Chhattisgarh, India. Journal of Microbiology and Infectious Diseases. 2022; 12: 1-5.
12. Hassett KJ, Benenato KE, Stebbins JS. Optimization of lipid nanoparticle formulation for mRNA delivery. Nature Reviews Materials. 2021; 6: 1-17.
13. Lisa A Jackson, Evan J Anderson, Nadine G Rouphael, Paul C Roberts, Mamodikoe Makhene, et al. An mRNA vaccine against SARS-CoV-2 Preliminary Report. N Engl J Med. 2020; 383: 1920-1931.
14. Kallen KJ, Fagerberg CR, Sæbø A. Development of a self-amplifying RNA vaccine against influenza. Journal of Virology. 2018; 92.
15. Karikó K, Muramatsu H, Welsh E. Suppression of RNA-mediated inflammatory responses by pseudouridine modification. Immunity. 2005; 23: 165-175.
16. Kis Z, Kontoravdi C, Shattock RJ, Shah N. Resources and cost-effective production of a clinical-grade self-amplifying mRNA vaccine. NPJ Vaccines. 2019; 4: 111.
17. https://www.modernatx.com/en-US/our-medicines/pipeline
18. Mueller SN, Russell AJ. mRNA vaccines for neglected tropical diseases. Vaccine. 2022; 40: 4875-4881.
19. Nam D, Lee Y, Choi H. Role of mRNA modifications in enhancing stability and translation efficiency for vaccine development. Journal of Biomedical Science 2023; 30: 1-11.
20. Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine development. Journal of Medical Virology. 2022; 94: 5240-5250.
21. Polack FP, Thomas SJ, Kitchin N, Absalon J. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383: 2603-2615.
22. Richner JM, Himansu S, Shresta S. A single-dose mRNA vaccine protects against Zika virus infection. Nature. 2017; 525: 301-305.
23. Saelens X, Bixler SL, Graham BS. mRNA vaccines against respiratory syncytial virus. Current Opinion in Virology. 2022; 52: 1-7.
24. Sahin U, Derhovanessian E, Özcan H. Personalized RNA mutanome vaccines mobilize T cells to target cancer neoantigens. Nature. 2017; 547: 222-226.
25. Sayour E, Singh R, Vohra P. An mRNA vaccine platform to boost immunotherapy in mouse models of cancer. Nature Biomedical Engineering. 2025.
26. Shattock RJ, Moore JP. In vivo gene delivery of mRNA-encoded Env trimer-nanoparticles for HIV vaccine development. Cell. 2022; 185: 4624-4638.
27. Shi M, Zhou W. The progress of mRNA vaccines and their clinical applications. International Journal of Molecular Sciences. 2021; 22: 7401.
28. Sun X, Su Y, Li R. mRNA vaccine development: addressing the challenges of logistics and global distribution. Frontiers in Immunology. 2023; 14: 110901.

29. U.S. FDA. FDA approves first vaccine for prevention of respiratory syncytial virus (RSV) disease in older adults. Press Release. 2023.
30. Vankayalapati H, Vellingiri B, Subramanian S. mRNA vaccines: the promise and peril of novel delivery systems beyond lipid nanoparticles. Expert Opinion on Drug Delivery. 2024; 21: 323-338.
31. Weissman D, Pardi N. mRNA vaccines for infectious diseases: Moving beyond COVID-19. Cell. 2022; 185: 4615-4623.
32. WHO Science Council. mRNA vaccine technology: a report on potential benefits and limitations. World Health Organization. 2023.
33. Witzigmann D, Wagner E. Recent advances in mRNA-based cancer immunotherapy. Molecular Therapy. 2022; 30: 522-532.
34. Wood SK, Jones AH. The role of public trust in the acceptance of new vaccine technologies. Vaccine. 2023; 41: 856-862.
35. Zhang S, Li Y, Wang K. A systematic review of self-amplifying mRNA vaccines for infectious diseases. Journal of Translational Medicine. 2021; 19: 1-14.
36. Zhu Y, Li G, Cheng X. Circular RNA vaccines for sustained antigen expression: a new paradigm in vaccine design. Advanced Drug Delivery Reviews. 2024; 172: 114639.
37. Singh N, Bhange K. Non-coding RNAs in viral infections: Regulators of host response and disease progression. Journal of Virology Research & Reports. 2025; 6.